Geneva, Feb. 2 -- International Clinical Trials Registry received information related to the study (NCT07354919) titled 'Axelopran in Advanced Cancers' on Jan. 19.
Study Type: Interventional
Study Design:
Allocation: Non-Randomized. Intervention model: Single Group Assignment. Primary purpose: Treatment. Masking: None (Open Label).
Primary Sponsor: HealthPartners Institute
Condition:
Breast Cancer
Lung Cancer
Pancreas Cancer
Prostate Cancer
Intervention:
Drug: axelopran
Recruitment Status: Not recruiting
Phase: Phase 2
Date of First Enrollment: March 1, 2026
Target Sample Size: 34
Countries of Recruitment:
United States
To know more, visit https://clinicaltrials.gov/study/NCT07354919
Disclaimer: Curated by HT Syndicatio...